Literature DB >> 17729389

HFE gene in primary and secondary hepatic iron overload.

Giada Sebastiani1, Ann-P Walker.   

Abstract

Distinct from hereditary haemochromatosis, hepatic iron overload is a common finding in several chronic liver diseases. Many studies have investigated the prevalence, distribution and possible contributory role of excess hepatic iron in non-haemochromatotic chronic liver diseases. Indeed, some authors have proposed iron removal in liver diseases other than hereditary haemochromatosis. However, the pathogenesis of secondary iron overload remains unclear. The High Fe (HFE) gene has been implicated, but the reported data are controversial. In this article, we summarise current concepts regarding the cellular role of the HFE protein in iron homeostasis. We review the current status of the literature regarding the prevalence, hepatic distribution and possible therapeutic implications of iron overload in chronic hepatitis C, hepatitis B, alcoholic and non-alcoholic fatty liver diseases and porphyria cutanea tarda. We discuss the evidence regarding the role of HFE gene mutations in these liver diseases. Finally, we summarize the common and specific features of iron overload in liver diseases other than haemochromatosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17729389      PMCID: PMC4611189          DOI: 10.3748/wjg.v13.i35.4673

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  185 in total

1.  Up-regulation of transferrin receptor 1 in chronic hepatitis C: Implication in excess hepatic iron accumulation.

Authors:  Hiroyuki Saito; Yoshinori Fujimoto; Takaaki Ohtake; Yasuaki Suzuki; Shinobu Sakurai; Yayoi Hosoki; Katsuya Ikuta; Yoshihiro Torimoto; Yutaka Kohgo
Journal:  Hepatol Res       Date:  2005-04       Impact factor: 4.288

2.  Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda.

Authors:  Z J Bulaj; J D Phillips; R S Ajioka; M R Franklin; L M Griffen; D J Guinee; C Q Edwards; J P Kushner
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

3.  The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor.

Authors:  J A Lebrón; A P West; P J Bjorkman
Journal:  J Mol Biol       Date:  1999-11-19       Impact factor: 5.469

4.  HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis.

Authors:  Andreas Erhardt; Andrea Maschner-Olberg; Claudia Mellenthin; Günther Kappert; Ortwin Adams; Andreas Donner; Reinhard Willers; Claus Niederau; Dieter Häussinger
Journal:  J Hepatol       Date:  2003-03       Impact factor: 25.083

5.  Hepcidin in iron overload disorders.

Authors:  George Papanikolaou; Michalis Tzilianos; John I Christakis; Dionisios Bogdanos; Konstantina Tsimirika; Julie MacFarlane; Y Paul Goldberg; Nikos Sakellaropoulos; Tomas Ganz; Elizabeta Nemeth
Journal:  Blood       Date:  2005-01-25       Impact factor: 22.113

6.  Duodenal ferritin synthesis in genetic hemochromatosis.

Authors:  A Pietrangelo; G Casalgrandi; D Quaglino; R Gualdi; D Conte; S Milani; G Montosi; L Cesarini; E Ventura; G Cairo
Journal:  Gastroenterology       Date:  1995-01       Impact factor: 22.682

7.  Experimental liver cirrhosis induced by alcohol and iron.

Authors:  H Tsukamoto; W Horne; S Kamimura; O Niemelä; S Parkkila; S Ylä-Herttuala; G M Brittenham
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

8.  Hepatitis C, iron status, and disease severity: relationship with HFE mutations.

Authors:  Bruce Y Tung; Mary J Emond; Mary P Bronner; Stuart D Raaka; Scott J Cotler; Kris V Kowdley
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

9.  Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.

Authors:  Harald Hofer; Christoph Osterreicher; Wolfgang Jessner; Melitta Penz; Petra Steindl-Munda; Friedrich Wrba; Peter Ferenci
Journal:  J Hepatol       Date:  2004-06       Impact factor: 25.083

10.  Changes in serum iron levels due to infection with hepatitis B virus.

Authors:  B S Blumberg; E D Lustbader; P L Whitford
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

View more
  9 in total

1.  Function of the hemochromatosis protein HFE: Lessons from animal models.

Authors:  Kostas Pantopoulos
Journal:  World J Gastroenterol       Date:  2008-12-07       Impact factor: 5.742

2.  Hemochromatosis gene mutations: prevalence and effects on pegylated-interferon and ribavirin therapy response in chronic hepatitis C in sardinia.

Authors:  Margherita Sini; Orazio Sorbello; Alberto Civolani; Luigi Demelia
Journal:  J Clin Exp Hepatol       Date:  2012-09-21

3.  The influence of liver fat deposition on the quantification of the liver-iron fraction using fast-kilovolt-peak switching dual-energy CT imaging and material decomposition technique: an in vitro experimental study.

Authors:  Tingting Xie; Yongbin Li; Guanyong He; Zhen Zhang; Qiao Shi; Guanxun Cheng
Journal:  Quant Imaging Med Surg       Date:  2019-04

Review 4.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

5.  Accelerated CCl4-induced liver fibrosis in Hjv-/- mice, associated with an oxidative burst and precocious profibrogenic gene expression.

Authors:  Giada Sebastiani; Kostas Gkouvatsos; Carmen Maffettone; Graziella Busatto; Maria Guido; Kostas Pantopoulos
Journal:  PLoS One       Date:  2011-09-22       Impact factor: 3.240

6.  Separation of hepatic iron and fat by dual-source dual-energy computed tomography based on material decomposition: an animal study.

Authors:  Jing Ma; Zhi-Qiang Song; Fu-Hua Yan
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

Review 7.  Iron at the Interface of Hepatocellular Carcinoma.

Authors:  Rossana Paganoni; André Lechel; Maja Vujic Spasic
Journal:  Int J Mol Sci       Date:  2021-04-15       Impact factor: 5.923

Review 8.  Hyperferritinemia-A Clinical Overview.

Authors:  Miriam Sandnes; Rune J Ulvik; Marta Vorland; Håkon Reikvam
Journal:  J Clin Med       Date:  2021-05-07       Impact factor: 4.241

9.  Improvement of chronic hepatitis B by iron chelation therapy in a patient with iron overload: A case report.

Authors:  Dong-Mei Zou; Dong-Dong Rong; Hong Zhao; Li Su; Wan-Ling Sun
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.